Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study

AIM: The current study evaluated the efficacy and tolerability of second-line afatinib in patients with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC) following chemotherapy. PATIENTS & METHODS: In this open-label, single-arm Phase IV study, patients with EGFRm+ (Del19/L858R)...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Lung Cancer Manag
Autors principals: Thongprasert, Sumitra, Geater, Sarayut L, Clement, Dana, Abdelaziz, Amr, Reyes-Igama, Jasmin, Jovanovic, Dragana, Alexandru, Aurelia, Schenker, Michael, Sriuranpong, Virote, Serwatowski, Piotr, Suresh, Sheethal, Cseh, Agnieszka, Gaafar, Rabab
Format: Artigo
Idioma:Inglês
Publicat: Future Medicine Ltd 2019
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6891940/
https://ncbi.nlm.nih.gov/pubmed/31807143
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/lmt-2019-0004
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars